CAPR Logo

Capricor Therapeutics, Inc. (CAPR) 

NASDAQ
Market Cap
$637.03M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
40 of 958
Rank in Industry
32 of 549

Largest Insider Buys in Sector

CAPR Stock Price History Chart

CAPR Stock Performance

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company …

Insider Activity of Capricor Therapeutics, Inc.

Over the last 12 months, insiders at Capricor Therapeutics, Inc. have bought $15M and sold $0 worth of Capricor Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Capricor Therapeutics, Inc. have bought $5.02M and sold $474.71M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Nippon Shinyaku Co Ltd (10 percent owner) — $15M.

The last purchase of 2,798,507 shares for transaction amount of $15M was made by Nippon Shinyaku Co Ltd (10 percent owner) on 2024‑09‑20.

List of Insider Buy and Sell Transactions, Capricor Therapeutics, Inc.

2024-09-20Purchase10 percent owner
2.8M
9.1284%
$5.36$15M+258.42%
2023-10-12Purchasedirector
410
0.0015%
$2.75$1,128+63.96%
2023-10-10Purchasedirector
10,000
0.0395%
$2.83$28,300+62.63%
2023-10-09Purchasedirector
5,083
0.02%
$2.82$14,334+66.55%
2023-10-06Purchasedirector
5,000
0.019%
$2.84$14,200+58.10%
2023-10-04Purchasedirector
2,500
0.0095%
$2.90$7,250+61.27%
2023-04-17Sale
14,772
$64,258.00$949.22M+3.50%
2023-03-28Sale
3,000
0.0118%
$4.06$12,180+6.59%
2022-06-29Sale
28,215
0.1163%
$3.77$106,371+19.68%
2022-06-29PurchaseCHIEF BUSINESS OFFICER
1,500
0.0062%
$3.76$5,643+19.68%
2022-06-27Sale
17,775
0.0736%
$4.44$78,921+1.59%
2017-05-09Purchase10 percent owner
2.29M
11.0606%
$3.10$7.1M-46.21%
2017-05-09Purchasedirector
20,000
0.0966%
$3.10$62,000-46.21%
2017-05-09Purchasedirector
50,000
0.2415%
$3.10$155,000-46.21%
2016-09-21Purchase10 percent owner
625,000
3.0673%
$3.20$2M-26.89%
2016-03-16Purchase10 percent owner
833,332
4.8375%
$2.40$2M+29.40%
2016-03-16Purchasedirector
182,738
1.0608%
$2.40$438,571+29.40%
2016-03-16Purchase10 percent owner
833,332
4.8375%
$2.40$2M+29.40%
2016-03-16PurchaseChief Executive Officer
30,456
0.1768%
$2.40$73,094+29.40%
2016-03-16Purchasedirector
200,000
1.161%
$2.40$480,000+29.40%

Insider Historical Profitability

15.38%
Nippon Shinyaku Co Ltd10 percent owner
7090351
15.5935%
$14.0110
CEDARS SINAI MEDICAL CENTER10 percent owner
4049959
8.9069%
$14.0140+25.52%
Marban Eduardo10 percent owner
3173354
6.979%
$14.0120<0.0001%
KASH PETER Mdirector
1596208
3.5105%
$14.0130
TANEN DAVID Mdirector
1520705
3.3444%
$14.0140

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$9.27M4.291.37M+17.2%+$1.36M<0.0001
BlackRock$2.59M1.2381,735+6.13%+$149,801.00<0.0001
Geode Capital Management$2.23M1.03328,477+3.88%+$83,391.31<0.0001
Susquehanna International Group$2.15M0.99316,260+112.09%+$1.13M<0.01
Millennium Management LLC$1.99M0.92293,041+1,292.91%+$1.85M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.